Effect of Valacyclovir on cognition and functions in schizophrenia
Not Applicable
- Conditions
- Health Condition 1: null- SchizophreniaHealth Condition 2: F20- Schizophrenia
- Registration Number
- CTRI/2013/10/004078
- Lead Sponsor
- The Stanley Medical Research Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Closed to Recruitment of Participants
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
•Written informed consent.
•Both genders, ages 18-50 years
•Schizophrenia / schizoaffective disorder (DSM IV).
•Duration of psychosis < 7 years.
•Stable dose of antipsychotic for > 1 month, continued throughout the study.
•Score 4 or more on one or more items of the Positive and Negative Syndrome Scale.
•Exposed to HSV-1: serum antibody assays.
Exclusion Criteria
•Substance abuse in the past month/dependence past 6 months.
•History / current medical /neurological illnesses e.g., epilepsy.
•Pregnancy.
•History of immune disorders, HIV infection, or receiving immune-suppressants.
•Receiving regular antiviral therapy.
•History of hypersensitivity to Valacyclovir.
•Mental retardation as defined in DSM IV.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To Improve cognitive function among HSV-1 exposed Early Course Schizophrenia patients.Timepoint: Baseline, zero week, 2 week, 4 week, 8 week, 12 week, 16 week, 20 week
- Secondary Outcome Measures
Name Time Method Overall daily functions among HSV-1 exposed Early course schizophreniaTimepoint: Baseline, zero week, 2 week, 4 week, 8 week, 12 week, 16 week, 20 week